Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986525 | 0.86 | KDM4E (0.35) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3986645 | 0.78 | KDM4E (0.39) | PKMHRH4RAD52UBE2NL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL5402957 | 0.73 | PKM (0.40) | PKMHRH4ALDH1A1POLBKMT2A | |
| Methylpiperazine SCHEMBL2263099 | 0.71 | PKM (0.44) | PKMHRH4HRH3RAD52UBE2N | |
| Methylpiperazine SCHEMBL2267453 | 0.71 | PKM (0.44) | PKMHRH4HRH3RAD52UBE2N | |
| SCHEMBL4745377 | 0.70 | CA2 (0.38) | PKMHRH4ALDH1A1POLBKMT2A | |
| SCHEMBL28361029 | 0.70 | SIGMAR1 (0.35) | PKM | |
| Trifluoroacetic Acid SCHEMBL28289038 | 0.69 | PKM (0.47) | PKMHRH4HRH3RAD52UBE2N | |
| Hydrochloric Acid SCHEMBL25387507 | 0.69 | HPGD (0.40) | PKMALDH1A1POLB | |
| Trifluoroacetic Acid SCHEMBL7814309 | 0.68 | PKM (0.49) | PKMHRH4RAD52UBE2NL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807423-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7498442-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080167295-A1 | Containing a nortropane ring, e.g., 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[2-hydroxy-3-(4-methanesulfonylpiperazin-1-yl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-10 | — | — | US | disclosed |
| US-7396933-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1807423-A2 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | Theravance, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006052889-A2 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167295-A1 | Containing a nortropane ring, e.g., 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[2-hydroxy-3-(4-methanesulfonylpiperazin-1-yl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; 5-HT4 receptor agonists | HTR5A, HTR4, HTR1A | PKM 4353/4885HRH4 61/4885HRH3 178/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | PKM 3256/4885HRH4 42/4885HRH3 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.